Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | CTSG | P08311 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 5/20 | 0.44 |
| ▸ | CES1 | P23141 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2823791 | 1.00 | SLC6A2 (0.53) | SLC6A2SLC6A3PGRADRA2AADRA2B | |
| SCHEMBL648332 | 0.89 | CES2 (0.47) | SLC6A2SLC6A3PGRADRA2AADRA2B | |
| SCHEMBL1248513 | 0.87 | LCK (0.55) | SLC6A2SLC6A3PGRADRA2AADRA2B | |
| SCHEMBL11754693 | 0.86 | LCK (0.58) | SLC6A2SLC6A3PGRADRA2AADRA2B | |
| SCHEMBL2871593 | 0.86 | LCK (0.58) | SLC6A2SLC6A3PGRADRA2AADRA2B | |
| SCHEMBL2336670 | 0.84 | PGR (0.52) | SLC6A2SLC6A3PGRADRA2AADRA2B | |
| SCHEMBL17644172 | 0.83 | SLC6A2 (0.54) | SLC6A2SLC6A3PGRADRA2AADRA2B | |
| SCHEMBL9449271 | 0.83 | NPC1 (0.49) | SLC6A2SLC6A3PGRADRA2AADRA2B | |
| SCHEMBL4937398 | 0.83 | SLC6A3 (0.54) | SLC6A2SLC6A3ADRA2BNPC1RAB9A | |
| SCHEMBL4935111 | 0.83 | SLC6A3 (0.56) | SLC6A2SLC6A3HTTCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961255-B2 | Imidazoles as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2021-03-30 | — | — | US | disclosed |
| US-20200299303-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2020-09-24 | — | — | US | disclosed |
| US-10633377-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-10562914-B2 | Imidazoles as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2020-02-18 | — | — | US | disclosed |
| US-10407420-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2019-09-10 | — | — | US | disclosed |
| US-10392381-B2 | Prevention and treatment of non-alcoholic fatty liver disease | OHIO UNIVERSITY (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190152987-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2019-05-23 | — | — | US | disclosed |
| US-10023567-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023567-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2018-07-17 | — | — | US | disclosed |
| WO-2017214505-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225845-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20110294822-A1 | Substituted Phenylpiperazinyl Aralkylalcohol Derivatives, Pharmaceutical Compositions Containing Such Derivatives and Uses Thereof | NHWA PHARMA. CORPORATION (CN) | 2011-12-01 | — | — | US | disclosed |
| US-20080234498-A1 | Pyrovalerone Analogues and Therapeutic Uses Thereof | PRESIDENT AND FELLOW OF HARVARD COLLEGE (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1673375-A2 | METHOD FOR THE IN SITU PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM OXAZABOROLIDINE-BORANE COMPLEXES, WHICH ARE USED IN ASYMMETRIC REDUCTION REACTIONS | PPG-Sipsy (FR) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005110955-A1 | SUBSTITUTED ACETOPHENOME AS MS REAGENTS | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005035540-A2 | METHOD FOR THE IN SITU PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM OXAZABOROLIDINE-BORANE COMPLEXES, WHICH ARE USED IN ASYMMETRIC REDUCTION REACTIONS | PPG-SIPSY (FR) | 2005-04-21 | — | — | WO | disclosed |
| EP-0073345-A2 | Sydnonimine derivatives, process for production thereof, and use thereof | Hidaka, Hiroyoshi (JP) | 1983-03-09 | — | — | EP | disclosed |
| US-4017631-A | MICROBIOCIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1977-04-12 | — | — | US | disclosed |
| US-3991202-A | ANTIMICROBIALS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234498-A1 | Pyrovalerone Analogues and Therapeutic Uses Thereof | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885SLC6A3 3/4885PGR 833/4885 |
| US-20120225845-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | CLN6, NLN, CLTC | SLC6A2 9/4885SLC6A3 18/4885PGR 4375/4885 |
| US-20190152987-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, DOT1L | SLC6A2 3915/4885SLC6A3 4069/4885PGR 2355/4885 |
| US-20200299303-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | DOT1L, KDM1B, KDM1A | SLC6A2 3896/4885SLC6A3 3970/4885PGR 2441/4885 |
| US-10392381-B2 | Prevention and treatment of non-alcoholic fatty liver disease | FABP1, LIPC, SLC10A1 | SLC6A2 969/4885SLC6A3 1323/4885PGR 2879/4885 |
| US-10407420-B2 | Imidazole and thiazole compositions for modifying biological signaling | TYRO3, FGFR1, STAT6 | SLC6A2 4571/4885SLC6A3 4310/4885PGR 1982/4885 |
| US-10562914-B2 | Imidazoles as histone demethylase inhibitors | KDM1B, KDM1A, DOT1L | SLC6A2 3915/4885SLC6A3 4069/4885PGR 2355/4885 |
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | PSEN2, CHAT, PSEN1 | SLC6A2 434/4885SLC6A3 367/4885PGR 3188/4885 |
| US-10633377-B2 | Imidazole and thiazole compositions for modifying biological signaling | TYRO3, FGFR1, STAT6 | SLC6A2 4570/4885SLC6A3 4307/4885PGR 1958/4885 |
| US-10023567-B2 | Imidazole and thiazole compositions for modifying biological signaling | FGFR1, TYRO3, STAT6 | SLC6A2 4536/4885SLC6A3 4221/4885PGR 1779/4885 |
| US-20110294822-A1 | Substituted Phenylpiperazinyl Aralkylalcohol Derivatives, Pharmaceutical Compositions Containing Such Derivatives and Uses Thereof | OPRL1, OPRK1, OPRD1 | SLC6A2 1800/4885SLC6A3 2006/4885PGR 699/4885 |
| US-10961255-B2 | Imidazoles as histone demethylase inhibitors | DOT1L, KDM1B, KDM1A | SLC6A2 3896/4885SLC6A3 3970/4885PGR 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.